Skye Bioscience to Present at Benzinga Biotech Small Cap Conference
18 mars 2021 08h45 HE
|
Skye Bioscience, Inc.
San Diego, Calif., March 18, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived...
Skye Bioscience’s Cannabinoid-Derived Drug Candidate, THCVHS, Demonstrates No Eye Irritation in Preclinical Assessment
16 mars 2021 08h30 HE
|
Skye Bioscience, Inc.
San Diego, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived...
Skye Bioscience Appoints Cannabinoid Science Experts Giovanni Appendino, PhD and Eduardo Muñoz, MD, PhD to Scientific Advisory Board
08 mars 2021 08h39 HE
|
Skye Bioscience, Inc.
San Diego, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic...
Skye Bioscience to Present at H.C. Wainwright Global Life Sciences Conference
03 mars 2021 08h37 HE
|
Skye Bioscience, Inc.
San Diego, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic...
Skye Bioscience to Participate in Investment Conferences in February
03 févr. 2021 09h09 HE
|
Skye Bioscience, Inc.
San Diego, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic...
Emerald Bioscience Launches Rebrand Including Name Change to Skye Bioscience
19 janv. 2021 08h30 HE
|
Skye Bioscience, Inc.
San Diego, Calif, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic...
Emerald Bioscience to Change Name and Trading Symbol Effective Tuesday, January 19th
15 janv. 2021 13h30 HE
|
Emerald Bioscience, Inc.
San Diego, Calif, Jan. 15, 2021 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“EMBI” or the “Company”), a biopharmaceutical company focused on developing proprietary,...
Emerald Bioscience to Present at the KCSA Cannabis Investor Conference
05 janv. 2021 08h30 HE
|
Emerald Bioscience, Inc.
San Diego, Calif, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald” or the “Company”), a biopharmaceutical company focused on developing differentiated, proprietary...
Emerald Bioscience Reports that Superior Reduction of Intraocular Pressure of its Unique Nanoemulsion Formulation of THCVHS is Published in Peer-Reviewed Journal
16 déc. 2020 08h30 HE
|
Emerald Bioscience, Inc.
Drug Delivery and Translational Research article highlights significantly better drug load and duration of activity of prodrug of THC compared to leading commercial drugs for treating glaucoma San...
Emerald Bioscience to Present at the Benzinga Global Small Cap Virtual Conference
07 déc. 2020 08h45 HE
|
Emerald Bioscience, Inc.
San Diego, Calif., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald” or the “Company”), a preclinical-stage biopharmaceutical company focused on developing...